COMPANION DIAGNOSTICS

 

 

Drugs developed and prescribed to those that need them. Companion diagnostics herald a new era in personalised medicine that will decrease trial costs and accelerate the delivery of effective cures to patients. Additionally, health systems will experience a reduced expenditure and improved patient experience.

THIS YEAR’S WORLD LEADING COMPANION DIAGNOSTICS SPEAKERS

 

 

 

Companion Diagnostics, Tuesday 2 November 2021

10:40

Networking Break

13:20

Networking Lunch Break

16:20

Networking Break

18:00

Neri & Sons Band & Networking Drinks Reception

last published: 19/Oct/21 21:45

Companion Diagnostics, Wednesday 3 November 2021

10:20

Networking Break + Speed Networking

Dominik Hartl
Companion Diagnostics
11:20

Non-Oncology-Based Companion Diagnostics

Sandra Smieszek
Companion Diagnostics
12:00

Viral genomics and clinical trials

Krystyna Nahlik
Companion Diagnostics
12:20

Tumor Mutational Burden Reference Materials and Beyond

Anguraj Sadanandam
Companion Diagnostics
12:40

Presentation

Anguraj Sadanandam, Reader in Stratified and Precision Medicine, Institute of Cancer Research
13:00

Networking Lunch Break

Panel discussion
Companion Diagnostics
14:00

Assessing the value of sequencing as a standard in clinical trials

  • Should sequencing trial cohorts become a standard in clinical trials?
  • Case studies demonstrating value
  • Saving trails and gaining new insights through genomic data
  • Other metadata that should be included as a standard
John Castle
Companion Diagnostics
14:40

Molecular Glue Degraders: From Serendipity to Rational Design

Monte Rosa’s QuEEN (Quantitative and Engineered Elimination of Neosubstrates) platform enables us to rationally discover molecular glue degraders (MGDs). QuEEN comprises:
  • Degron encyclopedia: A growing catalogue of over 1500 proteins identified through our AI-driven approach, containing proteins of diverse protein classes across therapeutic areas, including highly credentialed targets previously deemed undruggable.
  • Proprietary MGD library: A diverse and continuously growing chemical library of drug-like MGDs that are rationally designed based on our expertise in molecular glue anatomy
  • Glueomics toolbox: A tailored suite of biochemical, structural biology, cellular, proteomics and in silico screening tools that connect degrons to MGDs
Leveraging QuEEN, we have identified and validated MGDs to highly validated and therapeutically relevant but undruggable proteins.
Companion Diagnostics
14:40

OncoDNA Reserved

Jens K Habermann
Companion Diagnostics
15:00

BBMRI infrastructure supporting high quality samples and liquid biopsy translational research

16:00

Networking Break

18:00

Drinks Reception

last published: 19/Oct/21 21:45

Companion Diagnostics, Thursday 4 November 2021

last published: 19/Oct/21 21:45

GET INVOLVED AT BIODATA WORLD CONGRESS

 

 

TO SPONSOR


Alistair Wilmot
alistair.wilmot@terrapinn.com
0207 092 1174

 

 

TO SPEAK


Edward Glanville

edward.glanville@terrapinn.com
0207 092 1042

 

 

MARKETING OPPORTUNITIES


Onika Akhtar
onika.akhtar@terrapinn.com
0207 092 1034